Lexicon Pharmaceuticals (LXRX) Stock
Small biotech company developing medicines using human genetics. Here's the price, business snapshot, and what's worth knowing about Lexicon Pharmaceuticals in August 2026.
Lexicon Pharmaceuticals (LXRX) is a small-cap biotechnology company focused on discovering and developing medicines using human genetics and proprietary target validation tools. Its pipeline historically included drugs for metabolic and rare disease indications and has moved through licensing and collaboration arrangements with larger partners. With a market capitalisation around $523 million, Lexicon is primarily a research- and development-led business: clinical trial outcomes, regulatory decisions and partner deals are the main value drivers. Investors should note the sector’s typical features — binary clinical readouts, long timelines, and variable cash burn — and that revenues and profitability can be uneven or absent for extended periods. Diversification, careful review of recent SEC filings and attention to cash runway are important when assessing suitability. This summary is educational only and not personalised investment advice; stock prices can fall as well as rise and prospective investors should consider their own circumstances or consult a financial adviser.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Lexicon Pharmaceuticals' stock with a target price of $3.69, indicating growth potential.
Financial Health
Lexicon Pharmaceuticals is consistently generating strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can move the stock sharply; these events are worth watching, though outcomes are uncertain.
Partnering Impact
Licensing and collaborations can de‑risk programmes and provide funding, but depend on partner decisions and commercial execution.
Binary News Sensitivity
As a small‑cap biotech, share price may respond strongly to trial or regulatory results; maintain awareness of cash runway and dilution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
